TheStreet) -- Welcome to the first ever Biotech Stock Mailbag Live Chat. The floor is yours.
I'm here for the next hour or so to answer your biotech investing questions and hopefully spark some interactive debate on the hot biotech topics of the day. This chat only works if you participate, so please keep the questions and comments flowing in the box below.
The American Society of Clinical Oncology (ASCO) meeting kicks off in a few weeks, so we can talk about hot cancer stocks like
(EXEL - Get Report),
If you're a fan of large-cap biotech stocks, we can talk about how the emergence of oral multiple sclerosis drugs is affecting
(CELG - Get Report)
is dealing with controversy over secondary cancer risks tied to its most important drug Revlimid, so let's hash out the issue. How about discussing
and the pros and cons of offering its first shareholder dividend?
I never shy away from controversial topics, so let's argue about the prospects for
(SPPI - Get Report)
New drug launches are a big investment theme in 2011, so bring your questions and comments regarding
Human Genome Sciences
It's your Biotech Stock Mailbag Live Chat, so let's get started.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to: